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SUMMARY
BACKGROUND—Following a concerted public health response to the resurgence of tuberculosis 
(TB) in the United States in the late 1980s, annual TB incidence decreased substantially. However, 
no estimates exist of the number and cost savings of TB cases averted.
METHODS—TB cases averted in the United States during 1995–2014 were estimated: Scenario 1 
used a static 1992 case rate; Scenario 2 applied the 1992 rate to foreign-born cases, and a pre-
resurgence 5.1% annual decline to US-born cases; and a statistical model assessed human 
immunodeficiency virus and TB program indices. We applied the cost of illness to estimate the 
societal benefits (costs averted) in 2014 dollars.
RESULTS—During 1992–2014, 368 184 incident TB cases were reported, and cases decreased 
by two thirds during that period. In the scenarios and statistical model, TB cases averted during 
1995–2014 ranged from approximately 145 000 to 319 000. The societal benefits of averted TB 
cases ranged from US$3.1 to US$6.7 billion, excluding deaths, and from US$6.7 to US$14.5 
billion, including deaths.
CONCLUSIONS—Coordinated efforts in TB control and prevention in the United States yielded 
a remarkable number of TB cases averted and societal economic benefits. We illustrate the value 
of concerted action and targeted public health funding.
Abstract
A la suite d'une réponse concertée de santé publique à la résurgence de la tuberculose (TB) aux 
Etats-Unis à la fin des années 1980, l'incidence annuelle de la TB a considérablement décru. Il n'y 
a cependant pas d'estimations du nombre de cas de TB évités et des coûts épargnés.
Les cas de TB évités aux Etats-Unis entre 1995 et 2014 ont été estimés : le premier scénario a 
utilisé un taux statique de cas de 1992 ; le deuxième scénario a appliqué le taux de 1992 aux cas 
nés à l'étranger et un déclin annuel de 5,1% avant la résurgence, aux cas nés aux Etats-Unis ; un 
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modèle statistique a évalué les indices des programmes pour le virus de l'immunodéficience 
humaine et TB. Nous avons appliqué le coût de la maladie afin d'estimer les bénéfices pour la 
société (coûts évités) en dollars 2014.
Entre 1992 et 2014, 368 184 cas de TB ont été déclarés et le nombre de cas a diminué de deux 
tiers pendant cette période. Dans les scénarios et le modèle statistique, le nombre de cas de TB 
évités entre 1995 et 2014 allait d'environ 145 000 à 319 000. Les bénéfices sociaux des cas de TB 
évités allaient de US$3,1à US$6,7 milliards, en excluant les décès, et de US$6,7 à US$14,5 
milliards, en incluant les décès.
Les efforts coordonnés de prévention et de lutte contre la TB aux Etats-Unis ont abouti à un 
nombre remarquable de cas évités et de bénéfices sociaux. Nous illustrons la valeur d'une action 
concertée et d'un financement de santé publique ciblé.
Abstract
A raíz de la respuesta concertada de salud pública a la reaparición de la tuberculosis (TB) en los 
Estados Unidos al final de los años 1980, la incidencia anual de TB disminuyó de manera 
considerable. Sin embargo, no existen estimaciones sobre el número de casos evitados y el ahorro 
de costes.
Se llevó a cabo una estimación de los casos de TB evitados entre 1995 y el 2014 en los Estados 
Unidos; en la primera hipótesis se utilizó una tasa de incidencia estática a partir de 1992; en la 
segunda hipótesis se aplicó la tasa de 1992 a los casos nacidos en el extranjero y el 5,1% de la 
disminución anual en el país antes de la reaparición de la enfermedad a los casos nacidos en los 
Estados Unidos; y en un modelo estadístico se evaluaron los índices de los programas contra la TB 
y la infección por el virus de la inmunodeficiencia humana. Se aplicó el costo de la enfermedad 
con el fin de estimar la ganancia para la sociedad (costos evitados) en dólares del 2014.
De 1992 al 2014 se notificaron 368 184 casos nuevos de TB y se observó una disminución de dos 
tercios de los casos durante este período. Según las diferentes hipótesis y el modelo estadístico, el 
número de casos evitados de 1995 al 2014 osciló entre 145 000 y 319 000. Los casos evitados 
significaron una ganancia para la sociedad que osciló entre 3,1 y 6,7 mil millones de dólares al 
excluir las defunciones y entre 6,7 y 14,5 mil millones de dólares cuando se incluyeron.
En los Estados Unidos, los esfuerzos coordinados de control y prevención de la TB tuvieron como 
resultado un número notable de casos de TB evitados y considerables ganancias económicas para 
la sociedad. El estudio destaca el valor de la acción concertada y de la financiación orientada de la 
salud pública.
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REPORTED TUBERCULOSIS (TB) CASES in the United States declined substantially 
from 1953 to 1985 (Figure 1). However, between 1985 and 1992, the country experienced an 
unprecedented reversal in that long-standing trend.1 During this 8-year period, several 
outbreaks of multidrug-resistant TB (MDR-TB) occurred, predominantly affecting people 
with human immunodeficiency virus (HIV) infection in congregate settings (e.g., health care 
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facilities and prisons).2 TB incidence increased by 20%, with an estimated excess of 52 100 
TB cases.1 This situation required an urgent and comprehensive national reaction,3,4 
supported by new federal and state funding.5 The Centers for Disease Control and 
Prevention (CDC; Atlanta, GA, USA) coordinated the national and multi-agency response, 
which included:
1. Training of health care providers to improve the ability to diagnose and 
treat persons with TB disease
2. Improving laboratory diagnostic methods with universal drug 
susceptibility testing (DST) of initial clinical specimens that were culture-
positive for Mycobacterium tuberculosis complex6,7
3. Implementing infection control precautions in health care facilities and 
other congregate settings8
4. Strengthening state and local health department TB programs to undertake 
monitoring of treatment until cure and to conduct contact investigations,4,9 
and
5. Conducting programmatically relevant research.10,11
Following the implementation of these various measures, TB incidence decreased steadily 
between 1993 and 2014.12
The purpose of the present report is to quantify the public health benefits of the decline in 
TB incidence over the past two decades following the resurgence. We estimated the number 
and value of TB cases averted using two plausible scenarios. We also developed a statistical 
model using selected TB program indices.
MATERIALS AND METHODS
Data sources
We obtained the annual number of TB cases between 1953 and 2014 from data reported to 
the National Tuberculosis Surveillance System (NTSS) maintained by the CDC. NTSS 
includes diagnostic, clinical, and treatment data on TB cases from all 50 states, the District 
of Columbia, several large cities, and US territories.13 CDC began collecting data on M. 
tuberculosis culture conversion, DST, and HIV status in 1993. Yearly TB cases were 
stratified by patient birthplace (i.e., US-born and foreign-born) and by drug resistance status 
(e.g., MDR-TB or extensively drug-resistant TB [XDR-TB], and non-MDR/XDR-TB).
We also used data reported by state TB programs to the CDC with the average number of 
persons having contact with infectious (pulmonary, sputum smear-positive) TB patients. 
From 1993 until 1999, these numbers are from an unpublished database of CDC TB 
Program Reports, and for 2000 until 2012 from Aggregate Reports for TB Program 
Evaluation (ARPE).14
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We examined the total and annual percentage change (APC) in TB cases during 1992–2014, 
and constructed two scenarios to estimate the number of TB cases that might have occurred 
without the above-mentioned interventions. We developed a statistical model using selected 
TB program indices to further evaluate associations with TB cases averted. For each of the 
two scenarios and the statistical model, the estimated number of TB cases averted was 
calculated by subtracting the observed number of TB cases from the estimate.
Scenario 1: static 1992 TB case rate
We assumed that 1) the annual US TB incidence rate would remain static at the 1992 peak 
level of the resurgence (10.4 per 100 000 population); 2) the annual incidence rate of 
foreign-born TB cases would remain static at the 1992 rate (34.5/100 000); 3) US-born 
incident TB cases would be the difference of foreign-born estimated TB cases from total 
estimated TB cases; and 4) the number of averted MDR/XDR-TB US-born and foreign-born 
TB cases was calculable from actual annual proportions of TB cases who are MDR/XDR-
TB among US-born and foreign-born TB cases, respectively.
Scenario 2: static 1992 TB case rate for foreign-born, 5.1% APC decline for US-born
We assumed that 1) annual US-born TB incident cases would decline by 5.1% annually (the 
historic trend before the TB resurgence, APC for 1953–1985, computed from NTSS data, 
Figure 1); 2) the annual incidence rate of foreign-born TB cases would remain static at the 
1992 rate (34.5/100 000); 3) total TB cases were the sum of US-born and foreign-born 
estimated TB cases; and 4) the number of averted MDR/XDR-TB US-born and foreign-born 
TB cases was calculable from actual annual proportions of TB cases who are MDR/XDR-
TB among US-born and foreign-born TB cases, respectively.
Statistical model of TB program indices
We developed a statistical model with five TB indices identified by previous analyses as 
being most associated with the decline in TB incidence15,16 and HIV status. Indices included 
the percentage of TB cases alive at diagnosis and who:
1. had any use of directly observed therapy (DOT)
2. completed treatment and were alive within 1 year of treatment initiation, 
excluding TB that was meningeal, of the bone or joint, or the central 
nervous system, initially resistant to rifampin, or TB in children aged ≤14 
years that was miliary or diagnosed by a blood specimen that was positive 
for M. tuberculosis on culture or nucleic acid amplification test
3. were initially M. tuberculosis culture-positive, for which DST was 
conducted on the M. tuberculosis isolate
4. were initially M. tuberculosis culture-positive and ever had documented 
M. tuberculosis sputum culture conversion
5. had HIV co-infection (alive or dead at diagnosis) (except in California, 
which did not report HIV-TB to CDC from 2005 to 2010), and
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6. the average number of contacts elicited per M. tuberculosis sputum acid-
fast bacilli smear-positive TB case.
Based on publications by McKenna et al.15 and Lobato et al.,16 we assumed that 
improvements in indices of effective TB control and prevention in year t0 would affect the 
number of TB cases 2 years later (t0+2). Using NTSS data beginning in 1993 and ARPE data 
through 2012, we developed a linear regression model to estimate the number of TB cases in 
year t0+2 from associations with the above TB program indices in time t0. We found that two 
variables, sputum culture conversion and the percentage of TB patients who also had HIV, 
were statistically associated with the number of TB cases and had the greatest association 
with the decline in TB cases from 1995 to 2014.
This statistical model is represented as follows:
TB cases in year t0+2 = 32 207 − (314.3 * per cent sputum culture conversion in t0) + (669.1 
* per cent of patients with HIV in t0). R2 = 0.99
Using coefficients estimated in the model, and substituting in values for sputum culture 
conversion (65%) and the percentage of TB cases with HIV (16%) that represented values at 
the beginning of the time period, we estimated that there would be 22 485 (95% confidence 
interval [CI] 21 609–23 360) TB cases in each year if the sputum culture conversion rate 
remained static at 65% and if 16% of TB cases had HIV. The number of observed cases in 
each year was subtracted from the estimate of 22 485 and then summed to calculate the total 
number of averted TB cases.
Societal benefits of TB cases averted
We applied a cost of illness per estimated TB case averted to calculate the societal benefits 
(costs averted) in 2014 dollars of cases prevented for each scenario and the statistical model. 
In-patient and out-patient direct costs in 2010 dollars of non-MDR-TB reported and methods 
described in Shepardson et al.,17 were updated to 2014 dollars by using the Consumer Price 
Index for Medical Care.18 Direct costs in 2010 dollars of MDR- and XDR-TB were 
similarly updated to 2014 dollars.19 The value of premature deaths due to MDR-TB was 
published previously;19 however, there were no reported deaths among XDR-TB patients in 
that study, and we had to estimate non-MDR- and XDR-TB premature deaths as follows. For 
non-MDR-TB, we estimated, from an analysis of a cohort of >17 000 TB cases from 15 US 
study sites, that 72% of deaths with TB are because of TB;20 and, from the NTSS, that 9% 
of TB patients die during treatment or are diagnosed with TB at death.12 Thus, 72% × 9% = 
6.48% of the value of premature life lost was attributed to TB. Productivity losses due to 
premature deaths,21* updated to 2014 US dollars using the change in average hourly 
earnings, were estimated at US$24 214 for non-MDR-TB patients (US$373 671 with death 
at age 65 × 6.48% of patients having deaths caused by TB) and at US$64 153 for XDR-TB 
patients (US$926 653 with death at age of 55, the average age at death for MDR-TB 
patients19 multiplied by 6.92% of patients having deaths caused by TB—the actual 
*The present value of future earnings, based on data from the Bureau of Labor Statistics Current Population Survey, and household 
production were discounted at 3% annually. These are estimates from persons surveyed and might not be representative of populations 
not surveyed, including institutionalized persons.
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percentage in the published MDR-TB patient sample).19 These costs were added to the 
societal costs for non-MDR-TB17 and for XDR-TB.19 Societal costs, including premature 
deaths for MDR-TB, were calculated at the individual age at death of patients.19
The costs used to estimate the value of cases averted are summarized in the Table. Direct 
medical costs in 2014 dollars are estimated at US$17 000 per non-MDR/XDR-TB case, US
$150 000 per MDR-TB case, and US$482 000 per XDR-TB case. Societal cost estimates, 
excluding productivity losses due to premature deaths and rounded to the nearest thousand, 
are: US$20 000 per non-MDR/XDR-TB case, US$225 000 per MDR-TB case, and US$621 
000 per XDR-TB case. Including lost productivity because of premature death, the societal 
costs are estimated at US$44 000 per non-MDR/XDR-TB case, US$282 000 per MDR-TB 
case, and US$664 000 per XDR-TB case.
To allow comparison of equal time periods for the two scenarios and the model, the number 
and societal benefits of TB cases averted for each year and for the total period of 1995 to 
2014 were estimated.
RESULTS
Between 1992, when 26 673 cases were reported, and 2014, when 9421 cases were reported, 
a total of 368 184 incident TB cases occurred in the United States. The number of incident 
TB cases was reduced by nearly two thirds over the period, at an average APC decline of 
4.6%. Actual annual TB incidence from 1953 to 2014 is depicted in Figure 1, with 
projections for scenarios 1 and 2.
The estimated annual number of averted TB cases for the two scenarios and the model are 
shown in Figure 2. Figure 3 shows the overall averted TB cases stratified by US-born and 
foreign-born persons for both scenarios (the number of averted foreign-born TB cases was 
the same for Scenarios 1 and 2). The total numbers of averted TB cases during 1995–2014 
were respectively 318 948, 144 852, and 157 497 for scenarios 1 and 2 and the statistical 
model (Figure 2). Figure 4A shows increases in the annual percentage for four program 
indices, and a reduction in the annual percentage of HIV-infected TB cases during 1993–
2012. Figure 4B shows the average number of contacts elicited per M. tuberculosis sputum 
acid-fast bacilli smear-positive TB case during 1993–2012.
The number and value of TB cases averted is greatest using Scenario 1, and much lower for 
both Scenario 2 and the statistical model. Excluding lost productivity because of premature 
death, the societal benefits of averted TB cases were estimated at respectively US$6.7, US
$3.1 and US$3.4 billion for Scenario 1, Scenario 2, and the statistical model. Including lost 
productivity due to premature death, the societal benefits were respectively US$14.5, US
$6.7 and US$7.3 billion (Figure 5).
DISCUSSION
Our analysis estimates that 144 852–318 948 TB cases were averted between 1995 and 
2014, following the implementation of various TB control and prevention measures. In 
addition, we calculated the economic societal benefit accrued from the estimated averted 
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cases over an extended period in TB incidence, including specific estimates for cases averted 
and the benefits of preventing difficult-to-treat forms of MDR-TB. In addition to preventing 
TB suffering and morbidity, the societal economic benefit, excluding the value of premature 
deaths, of averting TB cases ranged from US$3.1 to US$6.7 billion in 2014 US dollars. 
When we included the value of premature deaths lost to TB, the societal benefit of these 
public health program interventions ranged between US$6.7 and US$14.5 billion over the 
period 1995–2014.
Our scenarios and model were selected to be cautious and avoid exaggerating the long-term 
benefits of these public health interventions. While the upward trend in TB cases due to the 
resurgence in the late 1980s could have continued into the 1990s, we relied on two 
conservative scenarios in estimating the upper and lower bounds of the averted TB cases 
(Figure 1). The regression model provided additional information about the association 
between TB case trends and the proportion of sputum culture-positive patients who 
converted to culture-negative during treatment, and the percentage of TB cases with HIV. 
Coincidentally, the estimates of the number of TB cases averted using the regression model 
and Scenario 2 are similar, possibly providing additional validation to estimates from 
Scenario 2. Sputum culture conversion reflects good management of TB disease, suggesting 
that an effective treatment regimen is taken for a sufficient period. This index also signals 
the practice of universal DST to guide the selection of the most effective TB treatment 
regimen, instituted in 1993.22 Recent evidence from a study in South Africa showed that 
prompt placement of TB patients on effective treatment rapidly reduces TB transmission.23 
McKenna et al. previously hypothesized that TB outbreaks affecting persons with HIV in the 
early 1990s were quelled by various measures that reduced TB transmission, including large 
investments in laboratory capacity and hospital infection control.15 While transmission 
among persons with HIV likely declined as a result of infection control measures, we found 
that the percentage of TB cases with HIV has remained a significant predictor of TB cases 
throughout the past two decades.
Hill et al. estimated future TB trends in association with different interventions, and divided 
the population into US-born and foreign-born.24 This stratification was maintained in two of 
our modeling scenarios, as the largest proportion of TB cases in the United States occurs in 
foreign-born persons (66% of reported TB cases in 2014). During the first decade following 
the peak annual TB incidence in 1992, when the larger proportion of cases occurred in US-
born persons, the larger number of averted TB cases was also in the US-born population. 
However, by 2003, averted TB cases in the foreign-born population exceeded the US-born in 
our most conservative scenario. Despite the remarkable progress in averting TB cases, 
accelerated declines remain necessary in both populations.
There are limitations to the two scenarios and statistical model. First, they might mask state, 
local, and country of origin level effects on TB cases and trends within those smaller units. 
Future analyses will examine these in depth. Second, the number of TB cases among 
foreign-born persons varies by country of origin, and US population estimates and trends of 
foreign-born persons might lack accuracy. Third, the statistical model is unable to predict 
with precision the impact of individual interventions. Last, cost estimates exclude out-of-
pocket costs to patients and the cost of investigating patients who present for medical 
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attention with signs and symptoms of TB disease but are subsequently determined not to 
have TB disease, and the value of preventing secondary transmission from the averted TB 
cases.
As a country, the United States provided global public health leadership by developing and 
publishing in 1989 the national strategic plan for the elimination of TB in the United 
States.25 Progress towards TB elimination, defined as annual TB incidence of fewer than one 
TB case per million population, was both reversed and threatened by the unprecedented 
resurgence of TB between 1985 and 1992. In response, various federal government agencies 
partnered with state and local public health departments, professional organizations, and 
academic institutions to design and implement research into new rapid laboratory diagnostic 
tools and treatment regimens, and used the data to develop, update, and implement evidence-
based guidelines. Through CDC TB cooperative agreements with health departments in all 
50 states, selected large cities, and US territories, the federal government has also provided 
technical and financial support to ensure prompt identification, treatment, and cure of 
persons with TB disease.9,26 In addition, these various health jurisdictions have implemented 
updated policies to mitigate economic obstacles to the diagnosis and treatment of TB, and 
legal statutes aimed at reducing the risk of airborne M. tuberculosis transmission.27 
Furthermore, these various entities have provided assistance in responding to community 
and institutional TB outbreaks, implementing infection control and preventing TB 
transmission in health care and congregate settings such as correctional facilities and 
homeless shelters, as well as preventing TB disease progression in latently infected 
populations at high risk.28 Successes have been described previously for New York City,29 
and for the rest of the country.15,16 These combined efforts undertaken in partnerships 
among non-governmental organizations, federal, state, and local health departments have 
produced longstanding success since 1993 in reducing the incidence of TB. Widespread 
introduction of antiviral treatment for persons with HIV has also resulted in remarkable 
reductions in TB incidence in the United States and Europe.30,31
We document remarkable progress achieved in the United States over the past two decades 
to prevent suffering, morbidity, costs of direct medical care, and deaths due to TB disease. 
Sustaining these gains, while crucial, is insufficient for accelerated progress towards TB 
elimination. As previously reported,24,25 an emphasis on targeted testing and treatment of 
persons with latent tuberculous infection is also required for TB elimination.
TB incidence in the United States is at its nadir, precariously accompanied by a renewed risk 
of complacency and the conditions that contributed to the 1985–1992 resurgence of TB.1,32 
The call to action by the US Institute of Medicine remains poignantly relevant 15 years later: 
‘The question yet to be answered is whether the renewed opportunity that now presents itself 
to move toward elimination of tuberculosis will be seized or whether tuberculosis will be 
subject to another period of neglect until the next resurgence.’32 This precise challenge is 
also being confronted globally by the World Health Organization's new End TB Strategy, 
which aims to ultimately eliminate TB.33 The last two decades of progress against TB in the 
United States has demonstrated that achieving these ambitious targets demands both a 
comprehensive approach and unrelenting effort.
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US TB incidence (1953–2014) and TB cases averted (1992–2014) for Scenarios 1 (static 
1992 TB case rate) and 2 (static 1992 TB case rate in foreign-born, 5.1% APC decline in 
US-born). TB = tuberculosis; APC = annual percentage change.
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The annual number of tuberculosis cases averted in the United States, 1995–2014. This 
image can be viewed online in color at http://www.ingentaconnect.com/content/iuatld/ijtld/
2016/00000020/00000007/art00016.
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The annual number of TB cases averted, US-born for Scenarios 1 and 2, and foreign-born 
for either scenario, 1995–2014. This image can be viewed online in color at http://
www.ingentaconnect.com/content/iuatld/ijtld/2016/00000020/00000007/art00016.
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Trends in TB program indices, 1993–2012; A) trends in TB indicators, 1993–2012; B) 
average number of contacts per TB case, 1993–2012. DOT=directly observed therapy; 
DST=drug susceptibility testing; HIV = human immunodeficiency virus; CA = California; 
TB = tuberculosis. This image can be viewed online in color at http://
www.ingentaconnect.com/content/iuatld/ijtld/2016/00000020/00000007/art00016.
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Societal benefits in 2014 billion dollars of tuberculosis cases averted, excluding and 
including lost productivity due to premature deaths, 1995–2014. This image can be viewed 
online in color at http://www.ingentaconnect.com/content/iuatld/ijtld/
2016/00000020/00000007/art00016.
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Table
The cost of TB illness per case, 2014 US dollars
Non-MDR-TB $US MDR-TB $US XDR-TB $US
Direct cost 17 000 150 000 482 000
Societal cost, excluding productivity lost due to premature deaths 20 000 225 000 621 000
Societal cost, including productivity lost due to premature deaths 44 000 282 000 664 000
TB = tuberculosis; MDR-TB = multidrug-resistant TB; XDR-TB = extensively drug-resistant TB.
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